Skip to main content
. 2020 Aug 5;9(8):712. doi: 10.3390/antiox9080712

Figure 5.

Figure 5

mRNA expression of peroxiredoxin (Prx), thioredoxin-1 (Trx-1), Trx-2, B-cell lymphoma 2 (Bcl-2), Bcl-xl, and B-cell lymphoma 2-associated X protein (Bax) in RF/6A cells detected using semi-quantitative PCR. RF/6A cells were pretreated with a high or low dose of fenofibrate or 1 h, then stimulated with 1 mM paraquat (PQ) for 24 h. In GW6471 (GW) treated groups, the cells were incubated with 10 μM GW6471 for 1 h before fenofibrate treatment. (a) Relative expression of Prx. (b) Relative expression of Trx-1. (c) Relative expression of Trx-2. (d) Relative expression of Bcl-2. (e) Relative expression of Bcl-xl. (f) Relative expression of Bax. (* p < 0.05, ** p < 0.01 between the control group and 1 mM PQ-stimulated group using Mann–Whitney U-test; # p < 0.05, ## p < 0.01 compared to only 1 mM PQ-stimulated group using Kruskal–Wallis test with post hoc Dunn’s test; † p < 0.05, †† p < 0.01 between GW6471 treated group and fenofibrate treated group (the same concentration of fenofibrate) using Mann–Whitney U-test; n = 3 in each group; β-actin was used as an internal control.).